Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating expenses:
Research and development	$ 1,256,542	$ 4,089,577
General and administrative	3,365,961	3,985,298
Total operating expenses	4,622,503	8,074,875
Other income (expense):
Interest income, net	256,410	1,971
Foreign currency (loss) gain	(13,797)	136,211
Total other income	242,613	138,182
Net loss	(4,379,890)	(7,936,693)
Other comprehensive loss:
Foreign currency translation	61,956	(65,505)
Total comprehensive loss	$ (4,317,934)	$ (8,002,198)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (1.34)	$ (7.25)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (1.34)	$ (7.25)
Weighted-average common shares outstanding, basic (in shares)	3,260,484	1,095,076
Weighted-average common shares outstanding, diluted (in shares)	3,260,484	1,095,076